InterMune (ITMN) fails to win FDA approval for a lung treatment that analysts estimated would...

|By:, SA News Editor

InterMune (ITMN) fails to win FDA approval for a lung treatment that analysts estimated would bring in more than $1B in annual sales. Outside advisers to the FDA had recommended approval of the drug in March. Shares -80.7% AH. (PR)